My current position is Associated Professor at the Cell Biology Department of the University of Seville. I was awarded with a FPU grant for the development of a doctoral thesis, which was supervised by Santiago Mateos Cordero, full professor in Cell Biology
Along my career, I have published numerous scientific papers in prestigious international journals as first author or author by correspondence. These contributions have been the result of postdoctoral research periods on topics such as DNA damage and repair in response to radio- and chemotherapy. I have numerous stays in European Centers of Excellence such as the Radiation Oncology and Biology (University of Oxford), Department of Genetics, Microbiology and Toxicology (University of Stockholm) and the Science for Life Laboratory (Karolinska Institute, Sweden), always in close collaboration with Professor Thomas Helleday (www.helleday.org). As a result of this collaboration, we published an essential paper on DNA replication stress (Petermann et al. 2010 Molecular Cell. IF 14).
Since 2013, our studies have been conducted to describe the cellular responses to hypomethylating agents commonly used in haematological disorders and leukemias, such as 5-azadC (decitabine) and Zebularine. These studies uncovered the efficacy of the combination of decitabine with PARP inhibitors (such as Olaparib) in acute leukemia cells (Orta et al., Nucleic Acids Research 2014). This data have a clear clinical applicability. Indeed, we were the first group discovering this combination and its mechanism. As a consequence, some clinical trials have emerged based on this combination ClinicalTrials.gov Identifier: NCT02878785 and ClinicalTrials.gov Identifier: NCT02878785
On the other hand, it is also worth mentioning my studies about the importance of the Fanconi Anemia pathway in the repair of decitabine-induced DNA lesions (Orta et al., Nucleic Acids Research 2013).
We have published data related with DNA damage responses after the treatment with Zebularine (Orta et al. DNA REPAIR 2017) and about the importance of Cockayne Syndrome proteins in the DNA repair of 5-azadC induced DNA lesions (Burgos-Morón et al. Oncotarget 2018).
These contributions, between others, reflect my experience in issues such as DNA damage and repair in response to radio- chemotherapy and cancer.
I have been the main researcher of two contracts (between the Karolinska Institute and the University of Seville). The first deals with the molecular mechanisms of DNA repair in response to decitabine. The second is aimed to characterize the repair mechanisms present in neuroblastoma stem cells in response to inhibitors of MTH1.
In relation to neuroblastoma, I was also the main researcher of a project granted by Progreso y Salud Foundation of the Andalusian Government. This project is titled "Biological efficacy of new Radiotherapy Modalities in Neuroblastoma Tumor Stem Cells. Modulation by DNA repair inhibitors (PI-0073-2014).
Currently I have been granted by the NEN Assotiation of Neuroblastoma patiens to develop a project of Neuroblastoma and MTH1inhibitors. In relation with that, I´m currently supervising a Thesis focused on the DNA repair and importance of MTH1 in Neuroblastoma. I am also supervising another thesis entitled “Influencia de los ácidos grasos de la dieta en la homeostasis y desarrollo de enfermedades inflamatorias crónicas; hepatocarcinoma, neurodegeneración y síndrome metabólico”, being the prequel to the project presented here
Recently I have also contributed to a paper where it is highlighted the importance of arginine synthesis on the efficacy of radiation as a therapy for high grade glioblastoma. The results have been published in the Journal of Clinical Investigation with a cite score of 20.8 for 2022 (Hajji et al JCI, 2022)
Data presented here is taken from Scopus. Identification number ID: 23088868400.
• Number of JCR papers: 26
• 2 six-year term (2006-2012/2012-2018).
• Number of total cites: 1242
• h index =15
My current position is Associated Professor at the Cell Biology Department of the University of Seville. I was awarded with a FPU grant for the development of a doctoral thesis, which was supervised by Santiago Mateos Cordero, full professor in Cell Biology
Along my career, I have published numerous scientific papers in prestigious international journals as first author or author by correspondence. These contributions have been the result of postdoctoral research periods on topics such as DNA damage and repair in response to radio- and chemotherapy. I have numerous stays in European Centers of Excellence such as the Radiation Oncology and Biology (University of Oxford), Department of Genetics, Microbiology and Toxicology (University of Stockholm) and the Science for Life Laboratory (Karolinska Institute, Sweden), always in close collaboration with Professor Thomas Helleday (www.helleday.org). As a result of this collaboration, we published an essential paper on DNA replication stress (Petermann et al. 2010 Molecular Cell. IF 14).
Since 2013, our studies have been conducted to describe the cellular responses to hypomethylating agents commonly used in haematological disorders and leukemias, such as 5-azadC (decitabine) and Zebularine. These studies uncovered the efficacy of the combination of decitabine with PARP inhibitors (such as Olaparib) in acute leukemia cells (Orta et al., Nucleic Acids Research 2014). This data have a clear clinical applicability. Indeed, we were the first group discovering this combination and its mechanism. As a consequence, some clinical trials have emerged based on this combination ClinicalTrials.gov Identifier: NCT02878785 and ClinicalTrials.gov Identifier: NCT02878785
On the other hand, it is also worth mentioning my studies about the importance of the Fanconi Anemia pathway in the repair of decitabine-induced DNA lesions (Orta et al., Nucleic Acids Research 2013).
We have published data related with DNA damage responses after the treatment with Zebularine (Orta et al. DNA REPAIR 2017) and about the importance of Cockayne Syndrome proteins in the DNA repair of 5-azadC induced DNA lesions (Burgos-Morón et al. Oncotarget 2018).
These contributions, between others, reflect my experience in issues such as DNA damage and repair in response to radio- chemotherapy and cancer.
I have been the main researcher of two contracts (between the Karolinska Institute and the University of Seville). The first deals with the molecular mechanisms of DNA repair in response to decitabine. The second is aimed to characterize the repair mechanisms present in neuroblastoma stem cells in response to inhibitors of MTH1.
In relation to neuroblastoma, I was also the main researcher of a project granted by Progreso y Salud Foundation of the Andalusian Government. This project is titled "Biological efficacy of new Radiotherapy Modalities in Neuroblastoma Tumor Stem Cells. Modulation by DNA repair inhibitors (PI-0073-2014).
Currently I have been granted by the NEN Assotiation of Neuroblastoma patiens to develop a project of Neuroblastoma and MTH1inhibitors. In relation with that, I´m currently supervising a Thesis focused on the DNA repair and importance of MTH1 in Neuroblastoma. I am also supervising another thesis entitled “Influencia de los ácidos grasos de la dieta en la homeostasis y desarrollo de enfermedades inflamatorias crónicas; hepatocarcinoma, neurodegeneración y síndrome metabólico”, being the prequel to the project presented here
Recently I have also contributed to a paper where it is highlighted the importance of arginine synthesis on the efficacy of radiation as a therapy for high grade glioblastoma. The results have been published in the Journal of Clinical Investigation with a cite score of 20.8 for 2022 (Hajji et al JCI, 2022)
Data presented here is taken from Scopus. Identification number ID: 23088868400.
• Number of JCR papers: 26
• 2 six-year term (2006-2012/2012-2018).
• Number of total cites: 1242
• h index =15
